Table 1.
Case notes review—maternal data
| 34–36+6 weeks N (%) | ≥ 37 weeks N (%) | |||
|---|---|---|---|---|
| Zambian sites | Indian sites | Zambian sites | Indian sites | |
| Total number of women | n = 69 | n = 15 | n = 98 | n = 44 |
| Maternal characteristics | ||||
| Mean (SD) age (years) | 26.5 (7.0) | 24.5 (3.2) | 25.8 (5.9) | 24.4. (4.2) |
| Primiparous | 28 (40.5) | 10 (66.7) | 57 (58.2) | 31 (70.5) |
| Singleton pregnancy | 64 (92.8) | 14 (93.3) | 94 (95.9) | 44 (100) |
| Ultrasound scan during pregnancy | 44 (63.8) | 8 (53.3)* | 63 (64.3) | 33 (75.0)* |
| At pre-eclampsia diagnosis | ||||
| SBP ≥ 140 or DBP ≥ 90 mmHg | 68 (98.6) | 11 (73.3)* | 93 (94.9) | 30 (68.2)* |
| ≥ 1 + protein on urine dipstick | 62 (89.9) | 8 (53.3) | 83 (84.7) | 21 (47.7) |
| Quantitative assessment of proteinuria | 0 | 0 | 0 | 0 |
| Creatinine tested | 18 (26.1) | 15 (100) | 23 (23.5) | 42 (95.5) |
| Liver enzymes tested | 24 (34.8) | 15 (100) | 24 (24.5) | 42 (95.5) |
| Platelets tested | 49 (71.0) | 15 (100) | 60 (61.2) | 41 (93.2) |
| Pre-eclampsia management | ||||
| Given antihypertensives | 61 (88.4) | 15 (100) | 88 (89.8) | 35 (79.5) |
| > 1 antihypertensive agent | 56 (81.6) | 8 (53.3) | 70 (71.4) | 14 (31.8) |
| Received antenatal corticosteroids | 42 (60.9) | 4 (26.7) | 9 (9.2) | 1 (2.3) |
| Received magnesium sulfate | 47 (68.1) | 12 (80.0) | 61 (62.2) | 19 (43.2) |
| Admitted antenatally | 66 (95.7) | 15 (100) | 90 (91.8) | 44 (100) |
| Onset of labour: | ||||
| Spontaneous | 22 (31.9) | 3 (20.0) | 43 (43.9) | 24 (54.5) |
| Induced | 25 (34.8) | 4 (26.7) | 28 (28.6) | 5 (11.4) |
| Pre-labour caesarean section | 22 (31.9) | 8 (53.3) | 27 (27.6) | 15 (34.1) |
| Not documented | 0 | 0 | 0 | 0 |
| Composite of severe maternal mortality and morbidity (N women) | 12 (17.4) | 6 (40.0) | 17 (17.3) | 9 (20.5) |
| Individual components (non-exclusive events): | ||||
| Death | 0 | 0 | 0 | 0 |
| Stroke | 0 | 0 | 0 | 0 |
| Eclampsia | 9 (13.0) | 3 (20.0) | 9 (9.2) | 5 (11.4) |
| Hysterectomy | 0 | 0 | 0 | 0 |
| Placental abruption | 0 | 3 (20.0) | 1 (1.0) | 0 |
| Pulmonary oedema | 0 | 0 | 0 | 0 |
| Blood transfusion | 3 (4.3) | 2 (13.3) | 7 (7.1) | 4 (9.1) |
| Severe hypertension | 60 (87.0) | 13 (86.7) | 68 (69.4) | 31 (70.5) |
| Other maternal complications: | 7 (10.1) | 4 (26.7) | 6 (6.1) | 4 (9.1) |
| Documented primary indication for delivery by clinician (N = induced plus pre-labour CS) | n = 47 | n = 12 | n = 55 | n = 20 |
| Severe pre-eclampsia | 34 (72.3) | 9 (75.0) | 40 (72.7) | 15 (75.0) |
| Eclampsia | 6 (12.8) | 3 (25.0) | 6 (10.9) | 5 (25.0) |
| Other | 6 (12.8) | 0 | 9 (16.4) | 0 |
| Hospital length of stay | n = 69 | n = 15 | n = 98 | n = 44 |
| Median (IQR) pre-delivery length of stay (days) | 1 (1–3) | 1 (1–1) | 1 (1–2) | 1 (1–1) |
| Median (IQR) postnatal length of stay (days) | 3 (2–5) | 8 (7–11) | 3 (2–4) | 7 (5–9) |
*Records of antenatal ultrasound or clinic visits not always available